/ITCI

ITCI Stock - Intra-Cellular Therapies, Inc.

Q: What is the analyst price target for ITCI?

Analyst price target information is not currently available for ITCI.

Q: What is ITCI's market cap?

Market capitalization information is not currently available for ITCI.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$131.87+0.00%

+$0.00 (+0.00%) • Apr 2

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+0.1%upside

Target: $132.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ITCI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.46

52W High$131.98

52W Low$64.09

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$680.85M	$464.37M	$249.13M	$81.71M	$22.53M
Gross Profit	$623.89M	$430.63M	$228.69M	$73.67M	$20.64M
Gross Margin	91.6%	92.7%	91.8%	90.2%	91.6%
Operating Income	$-116,721,000	$-159,381,000	$-263,626,000	$-285,688,125	$-231,227,631
Net Income	$-74,676,000	$-139,674,000	$-256,256,000	$-284,125,666	$-227,005,663
Net Margin	-11.0%	-30.1%	-102.9%	-347.7%	-1007.5%
EPS	$-0.72	$-1.46	$-2.72	$-3.50	$-3.23

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Visit Website

Earnings History & Surprises

ITCI

Beat Rate

65%

Last 20 quarters

Avg Surprise

+9.1%

EPS vs Estimate

Beats / Misses

13/6

1 met exactly

Latest EPS

$-0.16

Q1 2025

EPS Surprise History

Q2 23

+27.0%

$-0.46vs$-0.63

Q3 23

+27.4%

$-0.45vs$-0.62

Q4 23

+57.6%

$-0.25vs$-0.59

Q1 24

+31.8%

$-0.30vs$-0.44

Q2 24

+48.4%

$-0.16vs$-0.31

Q3 24

+11.1%

$-0.16vs$-0.18

Q4 24

-38.9%

$-0.25vs$-0.18

Q1 25

-100.0%

$-0.16vs$-0.08

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2025	Feb 21, 2025	$-0.08	$-0.16	-100.0%	✗ MISS
Q4 2024	Oct 30, 2024	$-0.18	$-0.25	-38.9%	✗ MISS
Q3 2024	Aug 7, 2024	$-0.18	$-0.16	+11.1%	✓ BEAT
Q2 2024	May 7, 2024	$-0.31	$-0.16	+48.4%	✓ BEAT
Q1 2024	Feb 22, 2024	$-0.44	$-0.30	+31.8%	✓ BEAT
Q4 2023	Nov 2, 2023	$-0.59	$-0.25	+57.6%	✓ BEAT
Q3 2023	Aug 3, 2023	$-0.62	$-0.45	+27.4%	✓ BEAT
Q2 2023	May 4, 2023	$-0.63	$-0.46	+27.0%	✓ BEAT
Q1 2023	Mar 1, 2023	$-0.62	$-0.45	+27.4%	✓ BEAT
Q4 2022	Nov 3, 2022	$-0.86	$-0.57	+33.7%	✓ BEAT
Q3 2022	Aug 9, 2022	$-0.79	$-0.92	-16.5%	✗ MISS
Q2 2022	May 10, 2022	$-0.93	$-0.78	+16.1%	✓ BEAT
Q1 2022	Mar 1, 2022	$-1.05	$-1.05	0.0%	= MET
Q4 2021	Nov 9, 2021	$-0.89	$-0.95	-6.7%	✗ MISS
Q3 2021	Aug 9, 2021	$-0.79	$-0.85	-7.6%	✗ MISS
Q2 2021	May 10, 2021	$-0.81	$-0.65	+19.8%	✓ BEAT
Q1 2021	Feb 25, 2021	$-0.85	$-0.76	+10.6%	✓ BEAT
Q4 2020	Nov 9, 2020	$-0.96	$-0.79	+17.7%	✓ BEAT
Q3 2020	Aug 10, 2020	$-0.94	$-0.96	-2.1%	✗ MISS
Q2 2020	May 7, 2020	$-0.98	$-0.73	+25.5%	✓ BEAT

Frequently Asked Questions about ITCI

What is ITCI's current stock price?

Intra-Cellular Therapies, Inc. (ITCI) is currently trading at $131.87 per share. The stock has moved +0.00% today.

What is the analyst price target for ITCI?

The average analyst price target for ITCI is $132.00, based on 1 analyst.

What sector is Intra-Cellular Therapies, Inc. in?

Intra-Cellular Therapies, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is ITCI's market cap?

Intra-Cellular Therapies, Inc. has a market capitalization of $14.05 billion, making it a large-cap company.

Does ITCI pay dividends?

No, Intra-Cellular Therapies, Inc. does not currently pay a dividend to shareholders.